Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.

IF 2.3 Q3 CLINICAL NEUROLOGY Neurodegenerative disease management Pub Date : 2023-02-01 DOI:10.2217/nmt-2022-0003

John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila

{"title":"Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.","authors":"John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila","doi":"10.2217/nmt-2022-0003","DOIUrl":null,"url":null,"abstract":"Aim: Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). Methods: Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. Results: The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. Conclusion: This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"23-34"},"PeriodicalIF":2.3000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2022-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). Methods: Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. Results: The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. Conclusion: This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在接受natalizumab或其他疗法治疗的多发性硬化症患者中描述“感觉良好的体验”。

目的:接受natalizumab治疗的复发-缓解型多发性硬化症(RRMS)患者有一种“感觉良好的体验”(FGE)。作者使用接受natalizumab或其他疾病改善疗法(other- dmt)治疗的RRMS患者的调查数据来描述FGE。方法:对使用在线患者社交网络MyMSTeam的RRMS患者的问卷数据进行分析。结果:调查包括347例患者(95例natalizumab;252 other-DMT)。natalizumab比其他dmt患者自我报告的FGE更多(62.1 vs 44.8%;P = 0.001)，以及其他身体、情感和认知方面的益处。结论:本研究表明，接受natalizumab治疗的患者比接受其他疾病改善疗法治疗的患者更常报告身体、情绪和认知方面的益处，并有助于表征患者报告的与FGE相关的因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neurodegenerative disease management CLINICAL NEUROLOGY-

CiteScore

4.30

自引率

0.00%

发文量